Treating mCRPC patients who have progressed on AR-directed therapy

Dr. Fabio Schutz addresses a key challenge when treating patients with metastatic castration resistant prostate cancer (mCRPC).  What do you do if they progress on an androgen receptor (AR) directed therapy?

DOWNLOAD THE SLIDES

Learn about shared decision-making conversations with your mCRPC patients using SHARE: A simple 5-step approach aimed at improving outcomes through engaging patients with metastatic castration resistant prostate cancer (mCRPC) in their own treatment decision.